Cargando…

Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany

Chronic lymphocytic leukemia (CLL) is the most common leukemia of adults in western countries. Therapy is indicated in symptomatic and advanced stages and has changed fundamentally since 2010 when rituximab, an anti-CD20 antibody, has been approved for treatment of CLL. Until then therapy had been b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kajüter, Hiltraud, Wellmann, Ina, Khil, Laura, Jöckel, Karl-Heinz, Zhang, Can, Fink, Anna-Maria, Hallek, Michael, Stang, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556420/ https://www.ncbi.nlm.nih.gov/pubmed/34716290 http://dx.doi.org/10.1038/s41408-021-00556-7

Ejemplares similares

Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany
por: Eisfeld, Christine, et al.
Publicado: (2023)

Breast cancer incidence and mammography screening among resettlers in Germany
por: Kaucher, Simone, et al.
Publicado: (2020)

Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort
por: Hense, Hans-Werner, et al.
Publicado: (2011)

DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy
por: Tsagiopoulou, Maria, et al.
Publicado: (2019)

The Incidence of Intestinal Gastric Cancer among Resettlers in Germany—Do Resettlers Remain at an Elevated Risk in Comparison to the General Population?
por: Lindblad, Anna, et al.
Publicado: (2020)

Excess mortality due to COVID-19 in Germany
por: Stang, Andreas, et al.
Publicado: (2020)

Cancer Incidence and Mortality Among Ethnic German Migrants From the Former Soviet Union
por: Kaucher, Simone, et al.
Publicado: (2018)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

A cross-national perspective of migration and cancer: incidence of five major cancer types among resettlers from the former Soviet Union in Germany and ethnic Germans in Russia
por: Jaehn, Philipp, et al.
Publicado: (2019)

Estimation of the Potentially Avoidable Excess Deaths Associated with Socioeconomic Inequalities in Cancer Survival in Germany
por: Jansen, Lina, et al.
Publicado: (2021)

Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy
por: Porrazzo, Marika, et al.
Publicado: (2020)

Nonmelanoma skin cancer in the Federal State of Saarland, Germany, 1995–1999
por: Stang, A, et al.
Publicado: (2003)

Divergent Patterns and Trends in Breast Cancer Incidence, Mortality and Survival Among Older Women in Germany and the United States
por: Jansen, Lina, et al.
Publicado: (2020)

Complete response of metastatic gastric cancer to chemoimmunotherapy
por: Ina, Kenji, et al.
Publicado: (2017)

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes
Publicado: (1981)

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy
por: Cohen, Jared A., et al.
Publicado: (2020)

Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
por: Huang, Qing, et al.
Publicado: (2022)

COVID-19 and the need of targeted inverse quarantine
por: Standl, Fabian, et al.
Publicado: (2020)

Characteristics of COVID-19 pandemic and public health consequences
por: Stang, Andreas, et al.
Publicado: (2020)

Colorectal Cancer among Resettlers from the Former Soviet Union and in the General German Population: Clinical and Pathological Characteristics and Trends
por: Mahanani, Melani Ratih, et al.
Publicado: (2021)

Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?
por: Cuneo, Antonio, et al.
Publicado: (2019)

A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia
por: Kay, Neil E., et al.
Publicado: (2016)

Excess mortality due to Covid-19? A comparison of total mortality in 2020 with total mortality in 2016 to 2019 in Germany, Sweden and Spain
por: Kowall, Bernd, et al.
Publicado: (2021)

Towards control of chronic lymphocytic leukemia using chemotherapy-free combinations
por: Hallek, Michael
Publicado: (2018)

Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
por: González-Rincón, Julia, et al.
Publicado: (2021)

Educational level, prevalence of hysterectomy, and age at amenorrhoea: a cross-sectional analysis of 9536 women from six population-based cohort studies in Germany
por: Stang, Andreas, et al.
Publicado: (2014)

On the gap between objective and perceived risks of COVID-19
por: Kowall, Bernd, et al.
Publicado: (2023)

Sequential and combination treatments with novel agents in chronic lymphocytic leukemia
por: Fürstenau, Moritz, et al.
Publicado: (2019)

Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia
por: Chen, Mo, et al.
Publicado: (2022)

Case-control study on uveal melanoma (RIFA): rational and design
por: Schmidt-Pokrzywniak, Andrea, et al.
Publicado: (2004)

Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?
por: Smolej, Lukáš, et al.
Publicado: (2021)

PB1921: IS CHEMOIMMUNOTHERAPY (CIT) HISTORY IN THE FIRST LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA?
por: Parbutt, Catherine, et al.
Publicado: (2023)

Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy
por: Emond, Bruno, et al.
Publicado: (2019)

Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment
por: Xu, Xiaoli, et al.
Publicado: (2022)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021)

Chemoimmunotherapy Administration Protocol Design for the Treatment of Leukemia through Mathematical Modeling and In Silico Experimentation
por: Valle, Paul A., et al.
Publicado: (2022)

Evaluation of a Prognostic Epigenetic Classification System in Chronic Lymphocytic Leukemia Patients
por: Grimm, Christina, et al.
Publicado: (2022)

PB1877: ADJUSTING SURVIVAL DATA FOR TREATMENT CROSSOVER IN THE ELEVATE-TN TRIAL BY USING A HISTORICAL COHORT OF PATIENTS TREATED WITH CHEMOIMMUNOTHERAPY IN FRONT-LINE CHRONIC LYMPHOCYTIC LEUKEMIA
por: Gaitonde, P., et al.
Publicado: (2022)

Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies
por: Robak, Tadeusz, et al.
Publicado: (2018)

Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study
por: Jeon, Youngwoo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7bndf6fju89uf400b15qid1s4p